ストックスクリーナーアプリを入手
9.06
1.09%
-0.10
アフターアワーズ：
9.20
0.14
+1.55%
Ocular Therapeutix Inc (OCUL) 最新ニュース
Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix Equity Grants Balance Growth Plans And Dilution Concerns - Yahoo Finance
Why It's Time To Keep A Close Eye On OCUL - RTTNews
Ocular Therapeutix (OCUL) Stock Analysis: A Biotech Gem With 171% Upside Potential - DirectorsTalk Interviews
Bearish Setup: Is Ocular Therapeutix Inc gaining market shareDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
Ocular Therapeutix Faces Declining Sales and Profitability Amid Market Sentiment Shift - Markets Mojo
Aug Closing: Will Ocular Therapeutix Inc stock hit new highs in YEARMarket Sentiment Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL) - The Globe and Mail
Will Ocular Therapeutix Inc stock hit new highs in YEARWeekly Risk Summary & Safe Entry Point Identification - baoquankhu1.vn
Ocular Therapeutix (NASDAQ:OCUL) Raised to Hold at Wall Street Zen - MarketBeat
(OCUL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
RBC Capital reiterates Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility - Sahm
Ocular Therapeutix Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com South Africa
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks - TipRanks
Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financials, Provides Business Highlights - VisionMonday.com
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates - Finviz
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says - marketscreener.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 8.8% on Better-Than-Expected Earnings - MarketBeat
Ocular Q4 Revenue Declines; Phase 3 Wet AMD Trial Data Expected Later This Month - Nasdaq
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Ocular Therapeutix: Q4 Earnings Snapshot - kare11.com
Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - TradingView
Ocular Therapeutix: Fourth Quarter Earnings Overview - Bitget
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - The Manila Times
Earnings Beat: Is Ocular Therapeutix Inc stock heavily shorted2025 Momentum Check & Fast Momentum Entry Tips - baoquankhu1.vn
Ocular Therapeutix (NASDAQ:OCUL) COO Sells $51,538.90 in Stock - MarketBeat
Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) COO Sells 5,455 Shares of Stock - MarketBeat
Notman, Ocular Therapeutix COO, sells $101,396 in stock By Investing.com - Investing.com Canada
Notman, Ocular Therapeutix COO, sells $101,396 in stock - Investing.com
Ocular Therapeutix Sees Unusually Large Options Volume (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Institutional Investors Lost 16% Last Week but Have Benefitted From Longer-term Gains - 富途牛牛
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Ocular Therapeutix Leadership Shifts And Valuation Gap Draw Investor Focus - Sahm
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Below 200-Day Moving AverageHere's Why - MarketBeat
Is Ocular Therapeutix Inc. undervalued by DCF analysisJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - Mfd.ru
A Look At Ocular Therapeutix (OCUL) Valuation After Mixed Earnings And New Executive Appointments - Sahm
Is Ocular Therapeutix’s (OCUL) New Commercial Hire Quietly Reframing Its Long‑Term Strategy? - Yahoo Finance
RSI Alert: Ocular Therapeutix (OCUL) Now Oversold - Nasdaq
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Biotechnology Innovator with 122% Upside Potential - DirectorsTalk Interviews
Responsive Playbooks and the OCUL Inflection - Stock Traders Daily
A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack - Yahoo Finance
Decliners Report: Is Ocular Therapeutix Inc undervalued by DCF analysisJuly 2025 Sentiment & Detailed Earnings Play Alerts - baoquankhu1.vn
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Bearish Setup: Whats Ocular Therapeutix Incs historical return2025 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
Ocular Therapeutix appoints Jason Robins interim CFO - The Globe and Mail
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 5.9%What's Next? - MarketBeat
Ocular Therapeutix appoints Jason Robins as interim CFO during Notman’s leave By Investing.com - Investing.com India
Ocular Therapeutix appoints Jason Robins as interim CFO during Notman’s leave - Investing.com India
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):